Teachers Advisors LLC raised its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 0.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 371,322 shares of the biopharmaceutical company’s stock after buying an additional 1,618 shares during the period. Teachers Advisors LLC owned 0.91% of Emergent Biosolutions worth $10,783,000 at the end of the most recent reporting period.
A number of other hedge funds have also made changes to their positions in EBS. State of Alaska Department of Revenue raised its stake in shares of Emergent Biosolutions by 2.7% in the first quarter. State of Alaska Department of Revenue now owns 3,820 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 100 shares during the last quarter. Envestnet Asset Management Inc. raised its stake in shares of Emergent Biosolutions by 29.6% in the fourth quarter. Envestnet Asset Management Inc. now owns 4,866 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 1,110 shares during the last quarter. Mason Street Advisors LLC raised its stake in shares of Emergent Biosolutions by 7.5% in the first quarter. Mason Street Advisors LLC now owns 8,087 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 564 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Emergent Biosolutions during the first quarter worth approximately $305,000. Finally, Nine Chapters Capital Management LLC raised its stake in shares of Emergent Biosolutions by 5.9% in the first quarter. Nine Chapters Capital Management LLC now owns 10,700 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 600 shares during the last quarter. 85.54% of the stock is owned by institutional investors.
Shares of Emergent Biosolutions, Inc. (NYSE:EBS) traded down 1.89% during trading on Friday, reaching $34.82. The company’s stock had a trading volume of 201,709 shares. Emergent Biosolutions, Inc. has a one year low of $24.47 and a one year high of $36.95. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 22.18 and a beta of 1.22. The company has a 50-day moving average price of $35.06 and a 200-day moving average price of $31.69.
Emergent Biosolutions (NYSE:EBS) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.26 by $0.13. The business had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The firm’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.05) earnings per share. On average, equities research analysts forecast that Emergent Biosolutions, Inc. will post $1.55 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Teachers Advisors LLC Acquires 1,618 Shares of Emergent Biosolutions, Inc. (NYSE:EBS)” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/19/teachers-advisors-llc-boosts-stake-in-emergent-biosolutions-inc-nyseebs-updated-updated-updated.html.
EBS has been the subject of several recent research reports. Zacks Investment Research lowered Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub raised Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $44.00.
In related news, Director Jerome M. Hauer sold 10,776 shares of Emergent Biosolutions stock in a transaction dated Tuesday, August 15th. The stock was sold at an average price of $35.83, for a total value of $386,104.08. Following the completion of the transaction, the director now directly owns 29,421 shares in the company, valued at $1,054,154.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Fuad El-Hibri sold 25,000 shares of Emergent Biosolutions stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $35.50, for a total value of $887,500.00. Following the completion of the transaction, the chairman now owns 1,655,216 shares of the company’s stock, valued at $58,760,168. The disclosure for this sale can be found here. Insiders have sold 60,776 shares of company stock valued at $2,186,104 over the last 90 days. Insiders own 16.50% of the company’s stock.
Emergent Biosolutions Company Profile
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
What are top analysts saying about Emergent Biosolutions Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Emergent Biosolutions Inc. and related companies.